Recently, overexpression of Rad51 was found as a negative predictive marker for neoadjuvant therapy using cisplatin/5-FU to treat esophageal cancers again arguing that high Rad51 levels may confer tumor cell resistance towards DNA damaging drugs [37]. The gene discussed is RAD51; the disease is esophageal cancer.